The tariff classification of a tinnitus treatment device from Ireland
No revocation or modification of this ruling appears in the Customs Bulletin issues read here (Nov 6, 2024 through Nov 18, 2026), where CBP publishes most such actions. That is not confirmation that the ruling is still in effect. Confirm its status with CBP before relying on it (ruling on CBP CROSS).
Ruling text
In your letter dated December 16, 2025, you requested a tariff classification ruling. The “Lenire® Tinnitus Treatment Device” (“Lenire device”), model CR-201, is a non-invasive bimodal neuromodulation device specifically designed for the adaptation and relief of tinnitus. It combines auditory and trigeminal nerve stimulation to alleviate symptoms associated with tinnitus.
The Lenire device consists of several component parts: a Controller (CR-201), a Tongue Tip (TP-101), a carry case (CE-401), a power supply (XP Power ACM06US05W-XZ1663A), and headphones (Austrian Audio Hi-X25BT). The Controller is a lightweight handheld device that coordinates the system’s bimodal neuromodulation by managing the timing, intensity, and synchronization of auditory stimulation (via Bluetooth headphones) with transmucosal tongue stimulation (via the Tongue Tip).
The Tongue Tip is an intra-oral stimulation device designed to deliver mild electrical pulses to the tongue, activating neural pathways to the brain. It consists of a slim, flexible probe with integrated electrodes and a microUSB connector for attachment to the Controller. The carry case is designed to hold the Tongue Tip and its cable within the body of the case. The power supply provides the necessary charging capability for the Lenire® Controller and, where applicable, the wireless headphones.
The headphones provide customized sounds to stimulate the auditory nerve. The Lenire device is prescription-only and must be fitted and configured by a suitably qualified audiologist or physician, who is experienced in the evaluation and management of tinnitus. Users intend to operate the device at home following clinical setup, with recommended daily sessions lasting 30 to 60 minutes.
Your letter proposes classifying the Lenire device under subheading 9018.90.8000, Harmonized Tariff Schedule of the United States (HTSUS), which covers “other” instruments and apparatus used in medical, surgical, dental, or veterinary sciences, and parts and accessories thereof. We disagree. Before classifying merchandise under a residual or “basket” provision like subheading 9018.90.80, HTSUS, we must first determine if it falls within the scope of a more specific subheading.
In this instance, because the Lenire device is electrically powered, it constitutes an “electro-medical instrument and appliance” under subheading 9018.90.75, HTSUS. Therefore, it is not classifiable under the residual provision of subheading 9018.90.80, HTSUS.
The applicable subheading for the Lenire device will be 9018.90.7560, HTSUS, which provides for “Instruments and appliances used in medical, surgical, dental or veterinary sciences, including scintigraphic apparatus, other electro-medical apparatus and sight-testing instruments; parts and accessories thereof: Other instruments and appliances and parts and accessories thereof: Other: Electro-medical instruments and appliances and parts and accessories thereof: Other: Other: Other therapeutic appliances and instruments: Other.” The general rate of duty will be free.
The text above is an excerpt. The official ruling, with its letterhead, signature and any attachments, is on CBP CROSS (N357069).